UNLABELLED: Clinical benefit of invasive functionally guided revascularization has been mostly investigated and proven for percutaneous coronary intervention. It has never been prospectively evaluated whether a systematic fractional flow reserve (FFR) assessment is also beneficial in guiding coronary artery bypass graft surgery (CABG). The objective of the GRAft patency after FFR-guided versus angiography-guIded CABG (GRAFFITI) trial was to compare an FFR-guided revascularization strategy to the traditional angiography-guided revascularization strategy for patients undergoing CABG. Patients were enrolled with significantly diseased left anterior descending or left main stem and at least one major coronary artery with angiographically intermediate stenosis (30-90% diameter stenosis) that was assessed by FFR. Thereafter, while the FFR values were kept concealed, cardiac surgeons decided their intended procedural strategy based on the coronary angiography alone. At this point, patients underwent 1:1 randomization to either an FFR-guided or an angiography-guided CABG strategy. In case the patient was randomized to angiography-guided arm, cardiac surgeons kept their intended procedural strategy, i.e., CABG was guided solely on the basis of the coronary angiography. In case the patient was randomized to the FFR-guided arm, FFR values were disclosed to the surgeons who revised the surgical protocol according to the functional significance of each coronary stenosis. The primary endpoint of the trial was the rate of graft occlusion at 12 months, assessed by coronary computed tomography or coronary angiography. The secondary endpoints were (1) length of postoperative hospital stay; (2) changes in surgical strategy depending upon FFR results (in FFR-guided group only); and (3) rate of major adverse cardiac and cerebrovascular events, i.e., composite of death, myocardial infarction, stroke, and any revascularization during the follow-up period. This study is the first prospective randomized trial investigating potential clinical benefits, associated with FFR-guided surgical revascularization. TRIAL REGISTRATION: NCT01810224.

Cardiovascular Center Na Homolce Hospital Prague Czech Republic

Cardiovascular Research Center Aalst OLV Clinic OLV Hospital Moorselbaan 164 B 9300 Aalst Belgium

Department of Cardiology and Internal Medicine University Hospital Brno and Medical Faculty of Masaryk University Brno Czech Republic

Department of Cardiology University Heart Center Graz Medical University of Graz Graz Austria

Division of Cardiology Department of Advanced Biomedical Sciences Federico 2 University Naples Italy

Division of Cardiology Department of Medicine University of Verona Verona Italy

Hospital Santa Marta Centro Hospitalar Lisboa Central Lisbon Portugal

Hungarian Institute of Cardiology Budapest Hungary

See more in PubMed

Eur Heart J. 2014 Oct 21;35(40):2831-8 PubMed

Ann Thorac Surg. 2007 Jun;83(6):2093-7 PubMed

J Am Coll Cardiol. 2010 Jun 22;55(25):2816-21 PubMed

N Engl J Med. 2014 Sep 25;371(13):1208-17 PubMed

Eur Heart J. 2010 Oct;31(20):2501-55 PubMed

N Engl J Med. 2018 Jul 19;379(3):250-259 PubMed

JACC Cardiovasc Imaging. 2009 Jul;2(7):816-24 PubMed

Circulation. 2009 Oct 13;120(15):1505-12 PubMed

Eur Heart J. 2017 Jul 1;38(25):1959-1968 PubMed

Lancet. 2015 Nov 7;386(10006):1853-60 PubMed

Circulation. 2013 Sep 24;128(13):1405-11 PubMed

Eur J Cardiothorac Surg. 2010 Sep;38 Suppl:S1-S52 PubMed

Eur Heart J. 2015 Dec 1;36(45):3182-8 PubMed

See more in PubMed

ClinicalTrials.gov
NCT01810224